QUality of life and Economic evaluation after neuroSTimulation for Epilepsy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26320

Enrollment

100

Registered

2020-11-03

Start date

2021-01-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

QOLIE-31, EQ-5D-5L standard version and proxy version 2, iMCQ (iMTA Medical Costs Questionnaire), iPCQ (iMTA Productivity Costs Questionnaire), IDQOL-16

Eligibility

Inclusion criteria

Inclusion criteria: Medically refractory epilepsy patients indicated for ANT DBS or VNS from january 2021 until january 2026 that will take place in Maastricht UMC+, Amsterdam UMC (location AMC) and Medisch Spectrum Twente.

Exclusion criteria

Exclusion criteria: Patients without a Dutch language proficiency or with a total IQ score lower than 50.

Design outcomes

Primary

Measure	Time frame
Disease specific quality of life	—

Secondary

Measure	Time frame
General quality of life, seizure frequency, care use, productivity	—

Contacts

Public ContactJacco Smeets

Maastricht University Medical Center (Neurosurgery Department)

jacco.smeets@mumc.nl043-3874041

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)